2023/04/06 更新

写真a

ヨシダ コウスケ
吉田 康将
YOSHIDA Kosuke
所属
大学院医学系研究科 特任助教
職名
特任助教

学位 1

  1. 博士(医学) ( 2020年3月   名古屋大学 ) 

 

論文 36

  1. Downregulation of miR‑10b‑5p facilitates the proliferation of uterine leiomyosarcoma cells: A microRNA sequencing‑based approach.

    Yoshida K, Yokoi A, Kitagawa M, Sugiyama M, Yamamoto T, Nakayama J, Yoshida H, Kato T, Kajiyama H, Yamamoto Y

    Oncology reports   49 巻 ( 5 )   2023年5月

     詳細を見る

    記述言語:英語   出版者・発行元:Oncology reports  

    Uterine leiomyosarcoma (ULMS) is one of the most aggressive gynecological malignancies. In addition, the molecular background of ULMS has not been fully elucidated due to its low incidence. Therefore, no effective treatment strategies have been established based on its molecular background. The present study aimed to investigate the roles of microRNAs (miRNAs/miRs) in the development of ULMS. Comprehensive miRNA sequencing was performed using six ULMS and three myoma samples, and revealed 53 and 11 significantly upregulated and downregulated miRNAs, respectively. One of the most abundant miRNAs in myoma samples was miR‑10b‑5p. The mean normalized read count of miR‑10b‑5p was 93,650 reads in myoma, but only 27,903 reads in ULMS. Subsequently, to investigate the roles of miR‑10b‑5p, gain‑of‑function analysis was performed using SK‑UT‑1 and SK‑LMS‑1 cell lines. The overexpression of miR‑10b‑5p suppressed cell proliferation and reduced the number of colonies. Moreover, miR‑10b‑5p increased the number of cells in the G1 phase. In conclusion, tumor‑suppressive miR‑10b‑5p was significantly downregulated in ULMS compared with in myoma; thus, miR‑10b‑5p may serve a specific role in sarcoma progression.

    DOI: 10.3892/or.2023.8523

    Scopus

    PubMed

  2. Novel therapeutic strategies targeting UCP2 in uterine leiomyosarcoma.

    Nagao Y, Yokoi A, Yoshida K, Sugiyama M, Watanabe E, Nakamura K, Kitagawa M, Asano-Inami E, Koya Y, Yoshihara M, Tamauchi S, Shimizu Y, Ikeda Y, Yoshikawa N, Kato T, Yamamoto Y, Kajiyama H

    Pharmacological research   189 巻   頁: 106693   2023年3月

     詳細を見る

    記述言語:英語   出版者・発行元:Pharmacological Research  

    Uterine leiomyosarcoma (ULMS) is a malignant stromal tumor arising from the myometrium with a poor prognosis and very limited response to current chemotherapy. This study aimed to identify novel targets for ULMS through a three-step screening process using a chemical library consisting of 1271 Food and Drug Administration-approved drugs. First, we evaluated their inhibitory effects on ULMS cells and identified four candidates: proscillaridin A, lanatoside C, floxuridine, and digoxin. Then, we subcutaneously or orthotopically transplanted SK-UT-1 cells into mice to establish mouse models. In vivo analyses showed that proscillaridin A and lanatoside C exerted a superior antitumor effect. The results of mRNA sequencing showed that uncoupling protein 2 (UCP2) was suppressed in the sirtuin signaling pathway, increasing reactive oxygen species (ROS) and inducing cell death. Moreover, the downregulation of UCP2 induced ROS and suppressed ULMS cell growth. Furthermore, analyses using clinical samples showed that UCP2 expression was significantly upregulated in ULMS tissues than in myoma tissues both at the RNA and protein levels. These findings suggested that UCP2 is a potential therapeutic target and can contribute to the development of novel therapeutic strategies in patients with ULMS.

    DOI: 10.1016/j.phrs.2023.106693

    Scopus

    PubMed

  3. Drug library screening identifies histone deacetylase inhibition as a novel therapeutic strategy for choriocarcinoma

    Watanabe Eri, Yokoi Akira, Yoshida Kosuke, Sugiyama Mai, Kitagawa Masami, Nishino Kimihiro, Yamamoto Eiko, Niimi Kaoru, Yamamoto Yusuke, Kajiyama Hiroaki

    CANCER MEDICINE   12 巻 ( 4 ) 頁: 4543 - 4556   2023年2月

     詳細を見る

    記述言語:英語   出版者・発行元:Cancer Medicine  

    Background: Choriocarcinoma is a rare and aggressive gynecological malignancy. The standard treatment is systemic chemotherapy as choriocarcinoma exhibits high chemosensitivity. However, refractory choriocarcinoma exhibits chemoresistance; thus, the prognosis remains very poor. This study aimed to identify novel therapeutic agents for choriocarcinoma by utilizing a drug repositioning strategy. Methods: Three choriocarcinoma cell lines (JAR, JEG-3, and BeWo) and a human extravillous trophoblast cell line (HTR-8/SVneo) were used for the analyses. The growth inhibitory effects of 1,271 FDA-approved compounds were evaluated in vitro screening assays and selected drugs were tested in tumor-bearing mice. Functional analyses of drug effects were performed based on RNA sequencing. Results: Muti-step screening identified vorinostat, camptothecin (S, +), topotecan, proscillaridin A, and digoxin as exhibiting an anti-cancer effect in choriocarcinoma cells. Vorinostat, a histone deacetylase inhibitor, was selected as a promising candidate for validation and the IC50 values for choriocarcinoma cells were approximately 1 μM. RNA sequencing and subsequent pathway analysis revealed that the ferroptosis pathway was likely implicated, and key ferroptosis-related genes (i.e., GPX4, NRF2, and SLC3A2) were downregulated following vorinostat treatment. Furthermore, vorinostat repressed tumor growth and downregulated the expression of GPX4 and NRF2 in JAR cell-bearing mice model. Conclusion: Vorinostat, a clinically approved drug for the treatment of advanced primary cutaneous T-cell lymphoma, showed a remarkable anticancer effect both in vitro and in vivo by regulating the expression of ferroptosis-related genes. Therefore, vorinostat may be an effective therapeutic candidate for patients with choriocarcinoma.

    DOI: 10.1002/cam4.5243

    Web of Science

    Scopus

    PubMed

  4. Preoperative serum microRNAs as potential prognostic biomarkers in ovarian clear cell carcinoma.

    Suzuki K, Yokoi A, Yoshida K, Kato T, Ochiya T, Yamamoto Y, Kajiyama H

    Journal of gynecologic oncology     2022年12月

     詳細を見る

    記述言語:英語  

    DOI: 10.3802/jgo.2023.34.e34

    PubMed

  5. Aberrant Activation of Cell-Cycle-Related Kinases and the Potential Therapeutic Impact of PLK1 or CHEK1 Inhibition in Uterine Leiomyosarcoma 査読有り

    Yoshida Kosuke, Yokoi Akira, Yamamoto Tomofumi, Hayashi Yusuke, Nakayama Jun, Yokoi Tsuyoshi, Yoshida Hiroshi, Kato Tomoyasu, Kajiyama Hiroaki, Yamamoto Yusuke

    CLINICAL CANCER RESEARCH   28 巻 ( 10 ) 頁: 2147 - 2159   2022年5月

     詳細を見る

    記述言語:英語   出版者・発行元:Clinical Cancer Research  

    Purpose: Uterine leiomyosarcoma is among the most aggressive gynecological malignancies. No effective treatment strategies have been established. This study aimed to identify novel therapeutic targets for uterine leiomyosarcoma based on transcriptome analysis and assess the preclinical efficacy of novel drug candidates. Experimental Design: Transcriptome analysis was performed using fresh-frozen samples of six uterine leiomyosarcomas and three myomas. The Ingenuity Pathway Analysis (IPA) was used to identify potential therapeutic target genes for uterine leiomyosarcoma. Afterward, our results were validated using three independent datasets, including 40 uterine leiomyosarcomas. Then, the inhibitory effects of several selective inhibitors for the candidate genes were examined using SK-UT-1, SK-LMS-1, and SKN cell lines. Results: We identified 512 considerably dysregulated genes in uterine leiomyosarcoma compared with myoma. The IPA revealed that the function of several genes, including CHEK1 and PLK1, were predicted to be activated in uterine leiomyosarcoma. Through an in vitro drug screening, PLK1 or CHEK1 inhibitors (BI-2536 or prexasertib) were found to exert a superior anticancer effect against cell lines at low nanomolar concentrations and induce cell-cycle arrest. In SK-UT-1 tumor-bearing mice, BI-2536 monotherapy remarkably suppressed tumorigenicity. Moreover, the prexasertib and cisplatin combination therapy inhibited tumor proliferation and prolonged the time to tumor progression. Conclusions: We identified upregulated expressions of PLK1 and CHEK1; their kinase activity was activated in uterine leiomyosarcoma. BI-2536 and prexasertib demonstrated a significant anticancer effect. Therefore, cell-cycle–related kinases may present a promising therapeutic strategy for the treatment of uterine leiomyosarcoma.

    DOI: 10.1158/1078-0432.CCR-22-0100

    Web of Science

    Scopus

    PubMed

    CiNii Research

  6. Chemical library-based drug repositioning strategy for choriocarcinoma therapy

    Watanabe Eri, Yokoi Akira, Yoshida Kosuke, Yamamoto Yusuke, Nishino Kimihiro, Niimi Kaoru, Kajiyama Hiroaki

    CANCER SCIENCE   113 巻   頁: 1501 - 1501   2022年2月

     詳細を見る

  7. Prognostic impact of extracellular miRNAs in patients with high-grade serous ovarian carcinoma

    Yoshida Kosuke, Yokoi Akira, Matsuzaki Juntaro, Kato Tomoyasu, Ochiya Takahiro, Kajiyama Hiroaki, Yamamoto Yusuke

    CANCER SCIENCE   113 巻   頁: 1788 - 1788   2022年2月

     詳細を見る

  8. Discovering novel therapeutic agents for uterine leiomyosarcoma

    Nagao Yukari, Yokoi Akira, Yoshida Kosuke, Watanabe Eri, Yoshihara Masato, Tamauchi Satoshi, Yoshikawa Nobuhisa, Yamamoto Yusuke, Kato Tomoyasu, Kajiyama Hiroaki

    CANCER SCIENCE   113 巻   頁: 1181 - 1181   2022年2月

     詳細を見る

  9. Clinical effects of cervical conization with positive margins in cervical cancer

    Nagao Yukari, Yokoi Akira, Yoshida Kosuke, Sumi Masanori, Yoshihara Masato, Tamauchi Satoshi, Ikeda Yoshiki, Yoshikawa Nobuhisa, Nishino Kimihiro, Niimi Kaoru, Kajiyama Hiroaki

    SCIENTIFIC REPORTS   11 巻 ( 1 ) 頁: 23288   2021年12月

     詳細を見る

    記述言語:英語   出版者・発行元:Scientific Reports  

    Radical surgery after cervical conization is a common approach for the treatment of cervical cancer. In some cases, disease progression is observed after positive margins at conization, but the effect of conization on disease progression remains unclear. Thus, the aim of this study was to investigate the clinical outcomes of positive margins at conization in cervical cancer. A total of 101 patients who underwent cervical conization before radical hysterectomy and pelvic lymph node dissection were considered eligible by reviewing medical records. The association between the positive margins and patient outcomes, including subsequent lymph node metastasis, was evaluated. The rate of lymphovascular space invasion (LVSI) positivity at radical surgery was significantly higher in patients with positive margins (p = 0.017) than in those with negative margins, although there was no significant difference in the rate of pelvic lymph node metastasis (p = 0.155). Moreover, there was no significant difference in the overall survival or progression-free survival between the two groups (p = 0.332 and 0.200, respectively). A positive margin at conization presented no significant prognostic disadvantage; thus, diagnostic conization is one of the most suitable treatment options for early-stage cervical cancer that is difficult to accurately assess.

    DOI: 10.1038/s41598-021-02635-y

    Web of Science

    Scopus

    PubMed

  10. Extracellular microRNA profiling for prognostic prediction in patients with high-grade serous ovarian carcinoma

    Yoshida Kosuke, Yokoi Akira, Matsuzaki Juntaro, Kato Tomoyasu, Ochiya Takahiro, Kajiyama Hiroaki, Yamamoto Yusuke

    CANCER SCIENCE   112 巻 ( 12 ) 頁: 4977 - 4986   2021年12月

     詳細を見る

    記述言語:英語   出版者・発行元:Cancer Science  

    High-grade serous ovarian carcinoma is a leading cause of death in female patients worldwide. MicroRNAs (miRNAs) are stable noncoding RNAs in the peripheral blood that reflect a patient’s condition, and therefore, they have received substantial attention as noninvasive biomarkers in various diseases. We previously reported the usefulness of serum miRNAs as diagnostic biomarkers. Here, we investigated the prognostic impact of the serum miRNA profile. We used the GSE106817 dataset, which included preoperative miRNA profiles of patients with ovarian malignancies. Excluding patients with other malignancy or insufficient prognostic information, we included 175 patients with high-grade serous ovarian carcinoma. All patients except four underwent surgery and received chemotherapy as initial treatment. The median follow-up period was 54.6 months (range, 3.5-144.1 months). Univariate Cox regression analysis revealed that higher levels of miR-187-5p and miR-6870-5p were associated with both poorer progression-free survival (PFS) and overall survival (OS), and miR-1908-5p, miR-6727-5p, and miR-6850-5p were poor prognostic indicators of PFS. The OS and PFS prognostic indices were then calculated using the expression values of three prognostic miRNAs. Multivariate Cox regression analysis showed that both indices were significantly independent poor prognostic factors (hazard ratio for OS and PFS, 2.343 [P =.015] and 2.357 [P =.005], respectively). In conclusion, circulating miRNA profiles can potentially provide information to predict the prognosis of patients with high-grade serous ovarian carcinoma. Therefore, there is a strong demand for early clinical application of circulating miRNAs as noninvasive biomarkers.

    DOI: 10.1111/cas.15154

    Web of Science

    Scopus

    PubMed

  11. Heat Shock Protein 105 as an Immunotherapeutic Target for Patients With Cervical Cancer

    Nosaka Kazuto, Suzuki Shiro, Yoshikawa Toshiaki, Shimomura Manami, Kitami Kazuhisa, Yoshida Kosuke, Yoshihara Masato, Kikkawa Fumitaka, Nakatsura Tetsuya, Kajiyama Hiroaki

    ANTICANCER RESEARCH   41 巻 ( 10 ) 頁: 4741 - 4751   2021年10月

     詳細を見る

    記述言語:英語   出版者・発行元:Anticancer Research  

    Background/Aim: Heat shock protein 105 (HSP105) is overexpressed in various cancers, but not in normal tissues. We investigated the expression levels of HSP105 in cervical cancer and the efficacy of immunotherapy targeting HSP105. Materials and Methods: Previously, we established human leukocyte antigen-A∗02:01 (HLA-A2) restricted HSP105 peptide-specific cytotoxic T lymphocyte (CTL) clones from a colorectal cancer patient vaccinated with an HSP105 peptide. Herein, we evaluated the expression of HSP105 in cervical cancer and cervical intraepithelial neoplasia. Moreover, we tested the effectiveness of an HLAA2-restricted HSP105 peptide-specific CTL clone against cervical cancer cell lines. Results: HSP105 was expressed in 95% (19/20) of examined cervical cancer tissues. Moreover, the HSP105 peptide-specific CTL clone recognized HSP105- and HLA-A∗02:01-positive cervical cancer cell lines and also showed that cytotoxicity against the cervical cancer cell lines depends on HSP105 peptide and HLA class I restricted manners. Conclusion: HSP105 could be an effective target for immunotherapy in patients with cervical cancer.

    DOI: 10.21873/anticanres.15289

    Web of Science

    Scopus

    PubMed

  12. Metabolome analysis reveals a diversity of cancer tissues in advanced epithelial ovarian cancer

    Yoshida Kosuke, Yoshikawa Nobuhisa, Kitami Kazuhisa, Tamauchi Satoshi, Ikeda Yoshiki, Yokoi Akira, Nishino Kimihiro, Niimi Kaoru, Kajiyama Hiroaki

    CANCER CELL INTERNATIONAL   21 巻 ( 1 ) 頁: 314   2021年6月

     詳細を見る

    記述言語:英語   出版者・発行元:Cancer Cell International  

    Background: Epithelial ovarian cancer remains one of the leading causes of cancer deaths among women worldwide, and advanced epithelial ovarian cancer frequently metastasizes to the omentum. The characteristics of metastatic cancer may differ from those of primary ovarian cancer and reflect the unique omental microenvironment. This study investigated metabolomic differences in epithelial ovarian cancers. Methods: Patients with advanced epithelial ovarian cancer were eligible for this study. Five patients underwent surgery and resection of paired primary ovarian and omental metastatic cancer at Nagoya University. Metabolome analysis was performed in these paired cancer and metastatic cancer tissues through a facility service (C-SCOPE) at Human Metabolome Technologies, Inc. The concentrations of 116 compounds were measured by CE-TOFMS and CE-QqQMS, and 30 metabolic parameters were calculated. For statistical analyses, Welch’s t-test was used for comparisons between two independent groups. Results: Metabolite profiles were all different, which reflects diversity among these cancer tissues. Of the measured compounds, urea was the only metabolite that was significantly decreased in omental metastatic cancers compared with the primary cancers (p = 0.031). Moreover, in omental metastatic cancers, the pentose phosphate pathway was more dominant than glycolysis. Furthermore, in some cases, lactic acids in omental metastatic cancers were markedly decreased compared with primary cancers. With regard to histological subtype, the total levels of amino acids, especially the percentage of glutamine, were significantly enriched in serous carcinomas compared with nonserous carcinomas (p = 0.004 and p = 0.001). Moreover, the reduced forms of glutathione and polyamines were also more abundant in serous carcinomas than in nonserous carcinomas (p = 0.025 and 0.048). Conclusions: The metabolite profiles differed depending on tumor location and histological subtype. Metabolome analysis may be a useful tool for identifying cancer diagnostic and prognostic markers.

    DOI: 10.1186/s12935-021-02014-7

    Web of Science

    Scopus

    PubMed

  13. miRNA signaling networks in cancer stem cells

    Yoshida Kosuke, Yamamoto Yusuke, Ochiya Takahiro

    REGENERATIVE THERAPY   17 巻   頁: 1 - 7   2021年6月

     詳細を見る

    記述言語:英語   出版者・発行元:Regenerative Therapy  

    Cancer stem cells (CSCs) are a small cell subpopulation in many cancer types and are involved in various processes of tumor progression, such as initiation, metastasis and recurrence. The distinguished features of CSCs include a variety of biological properties, including self-renewal, multidifferentiation, stemness marker expression, and resistance to chemotherapy and radiotherapy. Despite their great potential of clinical importance, the CSC signaling pathways are not well understood at the molecular level. MicroRNAs (miRNAs) are a class of endogenous noncoding RNAs that play an important role in the regulation of several cellular, physiological, and developmental processes. Aberrant miRNA expression is associated with many human diseases, including cancer. miRNAs have been implicated in the regulation of CSC properties; therefore, a better understanding of miRNA-induced modulation of CSC gene expression could aid in the identification of promising biomarkers and therapeutic targets. In the present review, we summarize the major findings of the impacts of miRNAs on CSC signaling networks; we then discuss the recent advances that have improved our understanding of CSC regulation by miRNA-mediated signaling networks and that may lead to the development of miRNA therapeutics specifically targeting CSCs.

    DOI: 10.1016/j.reth.2021.01.004

    Web of Science

    Scopus

    PubMed

  14. Significance of Concurrent Chemoradiotherapy as Primary Treatment in Patients with Metastatic Cervical Cancer

    Hattori Satomi, Yoshikawa Nobuhisa, Mogi Kazumasa, Yoshida Kosuke, Yoshihara Masato, Tamauchi Satoshi, Ikeda Yoshiki, Yokoi Akira, Nishino Kimihiro, Niimi Kaoru, Suzuki Shiro, Kajiyama Hiroaki

    CURRENT ONCOLOGY   28 巻 ( 3 ) 頁: 1663 - 1672   2021年6月

     詳細を見る

    記述言語:英語   出版者・発行元:Current Oncology  

    (1) This study investigated the prognostic impact of tumor size in patients with metastatic cervical cancer. (2) Methods: Seventy-three cervical cancer patients in our institute were stratified into two groups based on distant metastasis: para-aortic lymph node metastasis alone (IIIC2) or spread to distant visceral organs with or without para-aortic lymph node metastasis (IVB) to identify primary tumor size and concurrent chemoradiotherapy. (3) Results: The overall survival (OS) for patients with a tumor >6.9 cm in size was significantly poorer than that for patients with a tumor ≤6.9 cm in the IVB group (p = 0.0028); the corresponding five-year OS rates in patients with a tumor ≤6.9 and >6.9 cm were 53.3% and 13.4%, respectively. In the multivariate analysis, tumor size and primary treatment were significantly associated with survival in metastatic cervical cancer. (4) Conclusions: Tumor size ≤6.9 cm and concurrent chemoradiotherapy as the primary treatment were favorable prognostic factors for patients with metastatic cervical cancer.

    DOI: 10.3390/curroncol28030155

    Web of Science

    Scopus

    PubMed

  15. ChrXq27.3 miRNA cluster functions in cancer development

    Yoshida Kosuke, Yokoi Akira, Yamamoto Yusuke, Kajiyama Hiroaki

    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH   40 巻 ( 1 ) 頁: 112   2021年3月

     詳細を見る

    記述言語:英語   出版者・発行元:Journal of Experimental and Clinical Cancer Research  

    MicroRNAs (miRNAs) regulate the expression of their target genes post-transcriptionally; thus, they are deeply involved in fundamental biological processes. miRNA clusters contain two or more miRNA-encoding genes, and these miRNAs are usually coexpressed due to common expression mechanisms. Therefore, miRNA clusters are effective modulators of biological pathways by the members coordinately regulating their multiple target genes, and an miRNA cluster located on the X chromosome q27.3 region has received much attention in cancer research recently. In this review, we discuss the novel findings of the chrXq27.3 miRNA cluster in various types of cancer. The chrXq27.3 miRNA cluster contains 30 mature miRNAs synthesized from 22 miRNA-encoding genes in an ~ 1.3-Mb region. The expressions of these miRNAs are usually negligible in many normal tissues, with the male reproductive system being an exception. In cancer tissues, each miRNA is dysregulated, compared with in adjacent normal tissues. The miRNA-encoding genes are not uniformly distributed in the region, and they are further divided into two groups (the miR-506-514 and miR-888-892 groups) according to their location on the genome. Most of the miRNAs in the former group are tumor-suppressive miRNAs that are further downregulated in various cancers compared with normal tissues. miR-506-3p in particular is the most well-known miRNA in this cluster, and it has various tumor-suppressive functions associated with the epithelial–mesenchymal transition, proliferation, and drug resistance. Moreover, other miRNAs, such as miR-508-3p and miR-509-3p, have similar tumor-suppressive effects. Hence, the expression of these miRNAs is clinically favorable as prognostic factors in various cancers. However, the functions of the latter group are less understood. In the latter group, miR-888-5p displays oncogenic functions, whereas miR-892b is tumor suppressive. Therefore, the functions of the miR-888–892 group are considered to be cell type- or tissue-specific. In conclusion, the chrXq27.3 miRNA cluster is a critical regulator of cancer progression, and the miRNAs themselves, their regulatory mechanisms, and their target genes might be promising therapeutic targets.

    DOI: 10.1186/s13046-021-01910-0

    Web of Science

    Scopus

    PubMed

  16. Expression of the chrXq27.3 miRNA cluster in recurrent ovarian clear cell carcinoma and its impact on cisplatin resistance

    Yoshida Kosuke, Yokoi Akira, Sugiyama Mai, Oda Shingo, Kitami Kazuhisa, Tamauchi Satoshi, Ikeda Yoshiki, Yoshikawa Nobuhisa, Nishino Kimihiro, Niimi Kaoru, Suzuki Shiro, Kikkawa Fumitaka, Yokoi Tsuyoshi, Kajiyama Hiroaki

    ONCOGENE   40 巻 ( 7 ) 頁: 1255 - 1268   2021年2月

     詳細を見る

    記述言語:英語   出版者・発行元:Oncogene  

    Ovarian clear cell carcinoma (OCCC) is a histological subtype of epithelial ovarian cancer and exhibits dismal prognosis due to chemoresistance. Moreover, only few effective therapeutic options exist for patients with recurrent OCCC, and an understanding of its molecular characteristics is essential for the development of novel therapeutic approaches. In the present study, we investigated unique MicroRNAs (miRNA) profiles in recurrent/metastatic OCCC and the role of miRNAs in cisplatin resistance. Comprehensive miRNA sequencing revealed that expression of several miRNAs, including miR-508-3p, miR-509-3p, miR-509-3-5p, and miR-514a-3p was remarkably less in recurrent cancer tissues when compared with that in paired primary cancer tissues. These miRNAs are located in the chrXq27.3 region on the genome. Moreover, its expression was negative in omental metastases in two patients with advanced OCCC. In vitro analyses revealed that overexpression of miR-509-3p and miR-509-3-5p reversed cisplatin resistance and yes-associated protein 1 (YAP1) was partially responsible for the resistance. Immunohistochemistry revealed that YAP1 expression was inversely correlated with the chrXq27.3 miRNA cluster expression. In conclusion, these findings suggest that alteration of the chrXq27.3 miRNA cluster could play a critical role in chemoresistance and miRNAs in the cluster and their target genes can be potential therapeutic targets.

    DOI: 10.1038/s41388-020-01595-3

    Web of Science

    Scopus

    PubMed

  17. Extracellular miRNAs as Predictive Biomarkers for Glypican-3-Derived Peptide Vaccine Therapy Response in Ovarian Clear Cell Carcinoma

    Ukai Mayu, Yokoi Akira, Yoshida Kosuke, Suzuki Shiro, Shibata Kiyosumi, Kikkawa Fumitaka, Nakatsura Tetsuya, Kajiyama Hiroaki

    CANCERS   13 巻 ( 3 ) 頁: 1 - 18   2021年2月

     詳細を見る

    記述言語:英語   出版者・発行元:Cancers  

    Ovarian clear cell carcinoma (OCCC) has been treated with surgery and chemotherapy; however, the prognosis remains poor because of chemoresistance. Therefore, immunotherapies are attracting attention, including the GPC3 peptide vaccine, which improves overall survival. However, the response rate is limited and there are no sufficient predictive biomarkers that can identify responders before treatment. Our purpose was to identify circulating serum miRNAs as predictive biomarkers for response to GPC3 peptide vaccine. Eighty-four patients in a phase II trial of a GPC3 peptide vaccine were enrolled and miRNA sequencing was performed on their serum samples. Candidate miRNAs were selected from a group of 14 patients for whom treatment was responsive and validated in an independent group of 10 patients for whom treatment was responsive. Three markedly upregulated miRNAs, miR-375-3p, miR-193a-5p, and miR-1228-5p, were identified, and the combination of those miRNAs demonstrated high value in the prediction of the response. The origin of these miRNAs was assessed by referring to OCCC tissue miRNA profiles, and they were not identified as cancer tissue-related miRNAs. Functional annotation analysis suggested that they were associated with interferon-related pathways. The miRNAs identified herein have great potential to allow the realization of liquid biopsy for predicting the immunotherapy response and precision medicine.

    DOI: 10.3390/cancers13030550

    Web of Science

    Scopus

    PubMed

  18. Establishment of a patient-derived xenograft model and cell line of malignant transformation of mature cystic teratoma of the ovary

    Tamauchi Satoshi, Suzuki Shiro, Xuboya Chang, Yoshihara Masato, Yoshida Kosuke, Ikeda Yoshiki, Yoshikawa Nobuhisa, Kajiyama Hiroaki, Kikkawa Fumitaka

    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH   47 巻 ( 2 ) 頁: 713 - 719   2021年2月

     詳細を見る

    記述言語:英語   出版者・発行元:Journal of Obstetrics and Gynaecology Research  

    Aim: Malignant transformation of mature cystic teratoma (MTMCT) of the ovary is a rare gynecological malignancy and commonly arises in women older than 50 years of age. The most common histological type of MTMCT is squamous cell carcinoma (SCC), and the prognosis is extremely poor. Patient-derived xenograft (PDX) models are promising animal models for preclinical drug screening. Here, we report the generation of a new PDX model of MTMCT, and a new cell line established from the tumors of PDX model animals. Methods: Tumor tissue was obtained from a 32-year-old patient with MTMCT. To generate PDX, NSG (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ) mice, a strain of super-immunodeficient mice, were used. Tumor-bearing mice were sacrificed, followed by the collection of these tumors and re-transplantation into new NSG mice (in vivo passage). Tumor samples were also cultured in vitro. Adherent cells were continuously cultured and passaged, a cell line was established. Results: In the primary PDX mouse, tumor engraftment was confirmed 30 days after tumor implantation. After three times in vivo passage, we confirmed that the cryopreserved tumors could be engrafted even when transplanted into BALB/c nude mice. Using the tumor tissue at the time of the first in vivo passage, a new cell line NOSCC1 was established. PDX tumors and cell-line derived xenograft tumors exhibited similar morphology of SCC. Conclusion: We established a new PDX model of MTMCT and a new cell line of it, which may be important tools for the development of new therapies and the elucidation of the carcinogenic mechanisms of MTMCT.

    DOI: 10.1111/jog.14596

    Web of Science

    Scopus

    PubMed

  19. The role of chrXq27.3 miRNA cluster in advanced ovarian clear cell carcinoma

    Yoshida Kosuke, Yokoi Akira, Yoshihara Masato, Tamauchi Satoshi, Yoshikawa Nobuhisa, Nishino Kimihiro, Niimi Kaoru, Kikkawa Fumitaka, Kajiyama Hiroaki

    CANCER SCIENCE   112 巻   頁: 291 - 291   2021年2月

     詳細を見る

  20. Sarcopenia as a Predictor of Survival Among Patients With Organ Metastatic Cervical Cancer

    Yoshikawa Nobuhisa, Shirakawa Akira, Yoshida Kosuke, Tamauchi Satoshi, Suzuki Shiro, Kikkawa Fumitaka, Kajiyama Hiroaki

    NUTRITION IN CLINICAL PRACTICE   35 巻 ( 6 ) 頁: 1041 - 1046   2020年12月

     詳細を見る

    記述言語:英語   出版者・発行元:Nutrition in Clinical Practice  

    Background: This study was conducted to investigate the prognostic significance of sarcopenia in patients with organ metastatic cervical cancer. Methods: Accordingly, the data of 40 patients with organ metastatic cervical cancer treated at our institute from December 2004 to December 2017 were retrospectively analyzed. The correlation between clinicopathological characteristics and survival was then evaluated using univariate and multivariate analyses. Psoas muscle index (PMI), calculated from the psoas muscle area at the L3 vertebral-body level using computed tomography images obtained for pretreatment evaluation, was adopted as an index of sarcopenia. Results: The median follow-up period was 14 months (range, 1–91 months). Kaplan-Meier analysis showed a 3- and 5-year overall survival (OS) rate of 46.1% and 35.8% for all patients, respectively. Receiver operating characteristic curve maximizing the area under the curve showed that the optimal PMI for predicting 1-year survival was 3.72 cm2/m2. Patients with a PMI > 3.72 cm2/m2 had significantly better OS than those with a PMI ≤ 3.72 cm2/m2 (P =.046). Multivariate analysis revealed that only PMI was significantly associated with OS in patients with organ metastatic cervical cancer. Furthermore, patients with a PMI > 3.72 cm2/m2 who underwent concurrent chemoradiotherapy (CCRT) had a longer OS than those receiving other therapies (P <.001). Conclusions: High PMI was determined to be a favorable prognostic factor for patients with organ metastatic cervical cancer. Moreover, patients with organ metastatic cervical cancer who have a PMI > 3.72 cm2/m2 may benefit from CCRT as an initial treatment.

    DOI: 10.1002/ncp.10482

    Web of Science

    Scopus

    PubMed

  21. The clinical impact of intra- and extracellular miRNAs in ovarian cancer

    Yoshida Kosuke, Yokoi Akira, Kato Tomoyasu, Ochiya Takahiro, Yamamoto Yusuke

    CANCER SCIENCE   111 巻 ( 10 ) 頁: 3435 - 3444   2020年10月

     詳細を見る

    記述言語:英語   出版者・発行元:Cancer Science  

    Ovarian cancer is the most lethal gynecological cancer due to lack of early screening methods and acquired drug resistance. MicroRNAs (miRNAs) are effective post-transcriptional regulators that are transferred by extracellular vesicles, such as exosomes. Numerous studies have revealed that miRNAs are differentially expressed in epithelial ovarian cancer and act either as oncogenes or tumor suppressor genes. Cancer cells secrete exosomes containing miRNAs, which exert various effects on the components of the tumor microenvironment, including cancer-associated fibroblasts, macrophages, and adipocytes. Conversely, cancer cells also receive exosomes from these cells. As a result of cell-to-cell communication, epithelial ovarian cancer acquires a more aggressive phenotype and resistance to multiple drugs. In addition, some circulating miRNAs are protected from RNase degradation in the peripheral blood and can be potential non-invasive biomarkers. In particular, the combination of several circulating miRNAs enhances the accuracy of cancer screening. Likewise, comprehensive analyses revealed specific miRNA signatures in non-epithelial ovarian tumors and several miRNAs contributing to alterations of carcinogenic pathways. Overall, miRNAs play a crucial role in ovarian cancer progression. In this review, we discuss the emerging roles of intra- and extracellular miRNAs in ovarian cancers. In the near future, miRNAs will be practical biomarkers and computational deep learning will help in the clinical application of miRNAs. Moreover, miRNAs are potential therapeutic targets and agents, and there are ongoing clinical trials of miRNA replacement therapy. Therefore, accelerating research on miRNA might improve the prognosis of patients with ovarian cancer.

    DOI: 10.1111/cas.14599

    Web of Science

    Scopus

    PubMed

  22. The Preoperative Prognostic Nutritional Index for the Prediction of Outcomes in Patients with Early-Stage Ovarian Clear Cell Carcinoma

    Yoshikawa Nobuhisa, Yoshida Kosuke, Tamauchi Satoshi, Ikeda Yoshiki, Nishino Kimihiro, Niimi Kaoru, Suzuki Shiro, Kikkawa Fumitaka, Kajiyama Hiroaki

    SCIENTIFIC REPORTS   10 巻 ( 1 ) 頁: 7135   2020年4月

     詳細を見る

    記述言語:英語   出版者・発行元:Scientific Reports  

    The prognostic nutritional index (PNI), which reflects preoperative malnutrition, is useful for predicting the incidence of postoperative complications and has been reported in recent years to predict the long-term prognosis of various malignancies. The purpose of this study was to clarify the significance of PNI as a prognostic factor for early-stage clear cell ovarian carcinoma. A total of 82 patients with stage I–II (FIGO 2014) ovarian clear cell carcinoma undergoing primary surgery at our hospital from January 2005 to December 2017 were enrolled. PNI was calculated using the formula: 10 × serum albumin (g/ dL) + 0.005 × peripheral blood lymphocyte count (/mm3). Preoperative PNI exhibited relatively high area under the curve value (0.709) for 5 year survival, and the optimal cutoff value was 46.5. The overall survival was significantly shorter in the PNI-low group than in the PNI-high group. Multivariate analysis showed that high PNI was a significant independent prognostic factor for favorable prognosis (hazard ratio = 0.102, p = 0.010). There was no significant difference in recurrence-free survival between the two groups (p = 0.220), but the postrecurrence survival was significantly longer in the PNI-high group than in the PNI-low group (p = 0.0383). The preoperative PNI was a useful predictor of prognosis, even in early-stage ovarian clear cell carcinoma.

    DOI: 10.1038/s41598-020-64171-5

    Web of Science

    Scopus

    PubMed

  23. The role of additional hysterectomy after concurrent chemoradiation for patients with locally advanced cervical cancer

    Yoshida Kosuke, Kajiyama Hiroaki, Yoshihara Masato, Tamauchi Satoshi, Ikeda Yoshiki, Yoshikawa Nobuhisa, Nishino Kimihiro, Niimi Kaoru, Suzuki Shiro, Kikkawa Fumitaka

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   25 巻 ( 2 ) 頁: 384 - 390   2020年2月

     詳細を見る

    記述言語:英語   出版者・発行元:International Journal of Clinical Oncology  

    Background: The standard treatment for cervical cancer is chemoradiation although some patients showed treatment resistance. The purpose of this study was to investigate the clinical efficacy of surgery after chemoradiation for cervical cancer. Methods: Patients with FIGO stage IB2 to IIB cervical cancer were included in the study between 2005 and 2015. A total of 50 patients who underwent surgery after neoadjuvant chemoradiation and 76 patients who received only chemoradiation were compared. Baseline differences between the two groups were adjusted with inverse probability of treatment weighting method using propensity scores composed of the following independent variables: age, stage, tumor size, lymph node metastasis, and histological subtypes. Results: Median follow-up was 64.8 (range 4.8–143.9) months. After adjustment with inverse probability of treatment weighting, Kaplan–Meier curves showing adjusted progression-free survival and overall survival were significantly longer in the neoadjuvant chemoradiation compared with the chemoradiation-only group (p = 0.027 and p = 0.017, respectively). Moreover, in patients with squamous cell carcinoma, recurrence in previously irradiated field and recurrence both in and out of previously irradiated field were significantly decreased in the neoadjuvant chemoradiation compared with the chemoradiation-only group (3.1% and 18.4%, respectively; OR 0.142, p = 0.001]. Adverse events of surgery after chemoradiation were acceptable, although temporary hydronephrosis was frequently observed (23.1%). Conclusions: Surgery after chemoradiation reduced pelvic recurrence, and as a result, patients who underwent neoadjuvant chemoradiation showed more favorable survival outcomes compared with those who only underwent chemoradiation.

    DOI: 10.1007/s10147-019-01551-6

    Web of Science

    Scopus

    PubMed

  24. Plasma-activated medium promotes autophagic cell death along with alteration of the mTOR pathway

    Yoshikawa Nobuhisa, Liu Wenting, Nakamura Kae, Yoshida Kosuke, Ikeda Yoshiki, Tanaka Hiromasa, Mizuno Masaaki, Toyokuni Shinya, Hori Masaru, Kikkawa Fumitaka, Kajiyama Hiroaki

    SCIENTIFIC REPORTS   10 巻 ( 1 ) 頁: 1614   2020年1月

     詳細を見る

    記述言語:英語   出版者・発行元:Scientific Reports  

    The biological function of non-thermal atmospheric pressure plasma has been widely accepted in several types of cancer. We previously developed plasma-activated medium (PAM) for clinical use, and demonstrated that PAM exhibits a metastasis-inhibitory effect on ovarian cancer through reduced MMP-9 secretion. However, the anti-tumor effects of PAM on endometrial cancer remain unknown. In this study, we investigated the inhibitory effect of PAM on endometrial cancer cell viability in vitro. Our results demonstrated that AMEC and HEC50 cell viabilities were reduced by PAM at a certain PAM ratio, and PAM treatment effectively increased autophagic cell death in a concentration dependent manner. In addition, we evaluated the molecular mechanism of PAM activity and found that the mTOR pathway was inactivated by PAM. Moreover, our results demonstrated that the autophagy inhibitor MHY1485 partially inhibited the autophagic cell death induced by PAM treatment. These findings indicate that PAM decreases the viability of endometrial cancer cells along with alteration of the mTOR pathway, which is critical for cancer cell viability. Collectively, our data suggest that PAM inhibits cell viability while inducing autophagic cell death in endometrial cancer cells, representing a potential novel treatment for endometrial cancer.

    DOI: 10.1038/s41598-020-58667-3

    Web of Science

    Scopus

    PubMed

  25. Impact of age on clinicopathological features and survival of epithelial ovarian neoplasms in reproductive age

    Hanatani Maya, Yoshikawa Nobuhisa, Yoshida Kosuke, Tamauchi Satoshi, Ikeda Yoshiki, Nishino Kimihiro, Niimi Kaoru, Suzuki Shiro, Kawai Michiyasu, Kajiyama Hiroaki, Kikkawa Fumitaka

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   25 巻 ( 1 ) 頁: 187 - 194   2020年1月

     詳細を見る

    記述言語:英語   出版者・発行元:International Journal of Clinical Oncology  

    Background: Little is known about the effect of age on the prognosis of epithelial ovarian neoplasms. In the reproductive age, fertility-sparing surgery had been widely implemented. This study aimed to elucidate impact of age on the clinicopathologic characteristics and survival of epithelial ovarian neoplasms in the reproductive age. Methods: The clinical records of patients diagnosed as epithelial ovarian cancer or epithelial borderline ovarian tumor at the age of 40 years or younger at multiple institutions in the Tokai Ovarian Tumor Study Group were reviewed retrospectively. All patients were stratified into two age groups: group A (≤ 30 years) and group B (31–40 years). Univariate and multivariate analyses were performed to evaluate overall survival and disease-free survival. Results: A total of 583 patients (325 patients: cancer, 258 patients: borderline) were included. The median follow-up time was 62.0 months (range 1–270 months). Compared with group B, group A had a significantly higher rate of borderline tumor (66.7% vs. 32.7%, p < 0.001); stage I disease (85.9% vs. 70.4%, p < 0.001); mucinous type (69.2% vs. 35.6%, p < 0.001); conservative surgery (83.8% vs. 41.6%, p < 0.001); no adjuvant chemotherapy (67.2% vs. 44.7%, p < 0.001); and CA125 ≤ 35 U/mL (39.4% vs. 28.8%, p < 0.05). There was a significant difference in the overall survival (p = 0.0051) and the disease-free survival (p = 0.0039) between the two groups. Multivariate analysis revealed that the independent prognostic factors for the overall survival were age, stage, histology, and ascitic fluid cytology. Conclusion: In epithelial ovarian neoplasms, younger patients had a survival advantage over older patients.

    DOI: 10.1007/s10147-019-01550-7

    Web of Science

    Scopus

    PubMed

  26. Clinical Significance of Ubiquitin-associated Protein 2-like in Patients With Uterine Cervical Cancer

    Yoshida Kosuke, Kajiyama Hiroaki, Inami Eri, Tamauchi Satoshi, Ikeda Yoshiki, Yoshikawa Nobuhisa, Nishino Kimihiro, Utsumi Fumi, Niimi Kaoru, Suzuki Shiro, Shibata Kiyosumi, Nawa Akihiro, Kikkawa Fumitaka

    IN VIVO   34 巻 ( 1 ) 頁: 109 - 116   2020年

     詳細を見る

    記述言語:英語   出版者・発行元:In Vivo  

    Background: Ubiquitin-associated protein 2-like (UBAP2L) has been demonstrated to be associated with the progression of multiple types of cancer. However, the function of UBAP2L in uterine cervical cancer remains unclear. Materials and Methods: Between 2005 and 2015, 84 patients who underwent surgery were included in this study. The patients were stratified into two groups on the basis of immunohistochemical staining for UBAP2L, and survival analysis was performed. Moreover, loss-of-function analysis was performed using the cervical cancer cell lines CaSki and SiHa. Results: Based on immunohistochemistry, the overall survival in patients with low UBAP2L expression was significantly longer than that of those with high UBAP2L expression (p=0.045). The in vitro experiment revealed that knockdown of UBAP2L remarkably inhibited cell proliferation in both live cell imaging and the MTS assay. Conclusion: Patients with high UBAP2L expression had unfavorable prognosis and UBAP2L appears to play an important role in proliferation.

    DOI: 10.21873/invivo.11751

    Web of Science

    Scopus

    PubMed

  27. The usefulness of bevacizumab for relief from symptomatic malignant ascites in patients with heavily treated recurrent ovarian cancer

    Shimizu Yusuke, Kajiyama Hiroaki, Yoshida Kosuke, Tamauchi Satoshi, Nakanishi Toru, Kikkawa Fumitaka

    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH   45 巻 ( 12 ) 頁: 2435 - 2439   2019年12月

     詳細を見る

    記述言語:英語   出版者・発行元:Journal of Obstetrics and Gynaecology Research  

    Aim: Accumulation of ascites fluid is a major obstacle in the late phase of epithelial ovarian cancer. However, there is no consensus on a specific treatment for malignant ascites. The present study evaluated the clinical benefit of half-dose bevacizumab therapy (7.5 mg/kg every 3–4 weeks). Methods: This was a single-arm interventional study performed at Aichi Cancer Center Hospital. Four patients with platinum-resistant epithelial ovarian cancer and symptomatic malignant ascites were no longer considered candidates for standard chemotherapy. As a palliative approach, half-dose bevacizumab therapy (7.5 mg/kg every 3–4 weeks) was used with informed consent. The clinical data of these patients were retrospectively reviewed. Results: All patients had been heavily pretreated and showed progressive disease. Thus, standard chemotherapy was no longer feasible, and palliative paracentesis for malignant ascites was clinically needed. Among the four patients, three did not require additional paracentesis after bevacizumab therapy, and there were no adverse events. One patient needed paracentesis owing to lymphorrhea. Conclusion: The use of bevacizumab therapy as a palliative approach for malignant ascites might be an option in patients with terminal-stage ovarian cancer. However, further evaluation is needed with regard to the possibility of severe side effects and medical expenses.

    DOI: 10.1111/jog.14112

    Web of Science

    Scopus

    PubMed

  28. Unique miRNA profiling of squamous cell carcinoma arising from ovarian mature teratoma: comprehensive miRNA sequence analysis of its molecular background

    Yoshida Kosuke, Yokoi Akira, Kagawa Takumi, Oda Shingo, Hattori Satomi, Tamauchi Satoshi, Ikeda Yoshiki, Yoshikawa Nobuhisa, Nishino Kimihiro, Utsumi Fumi, Niimi Kaoru, Suzuki Shiro, Shibata Kiyosumi, Kajiyama Hiroaki, Yokoi Tsuyoshi, Kikkawa Fumitaka

    CARCINOGENESIS   40 巻 ( 12 ) 頁: 1435 - 1444   2019年12月

     詳細を見る

    記述言語:英語   出版者・発行元:Carcinogenesis  

    Owing to its rarity, the carcinogenesis and molecular biological characteristics of squamous cell carcinoma arising from mature teratoma remain unclear. This study aims to elucidate the molecular background of malignant transformation from the aspects of microRNA (miRNA) profiling. We examined 7 patients with squamous cell carcinoma and 20 patients with mature teratoma and extracted their total RNA from formalin-fixed paraffin-embedded tissues. Then we prepared small RNA libraries and performed comprehensive miRNA sequencing. Heatmap and principal component analysis revealed markedly different miRNA profiling in cancer, normal ovarian and mature teratoma tissues. Then we narrowed down cancer-related miRNAs, comparing paired-cancer and normal ovaries. Comparisons of cancer and mature teratoma identified two markedly upregulated miRNAs (miR-151a-3p and miR-378a-3p) and two markedly downregulated miRNAs (miR-26a-5p and miR-99a-5p). In addition, these findings were validated in fresh cancer tissues of patient-derived xenograft (PDX) models. Moreover, several miRNAs, including miR-151a-3p and miR-378a-3p, were elevated in the murine plasma when tumor tissues were enlarged although miR-26a-5p and miR-99a-5p were not elucidated in the murine plasma. Finally, we performed target prediction and functional annotation analysis in silico and indicated that targets genes of these miRNAs markedly correlated with cancer-related pathways, including 'pathway in cancer' and 'cell cycle'. In conclusion, this is the first study on miRNA sequencing for squamous cell carcinoma arising from mature teratoma. The study identified four cancer-related miRNAs that were considered to be related to the feature of malignant transformation. Moreover, miRNAs circulating in the murine plasma of the PDX model could be novel diagnostic biomarkers.

    DOI: 10.1093/carcin/bgz135

    Web of Science

    Scopus

    PubMed

  29. Prognostic value of neutrophil-to-lymphocyte ratio in early-stage ovarian clear-cell carcinoma

    Yoshida Kosuke, Yoshikawa Nobuhisa, Shirakawa Akira, Niimi Kaoru, Suzuki Shiro, Kajiyama Hiroaki, Kikkawa Fumitaka

    JOURNAL OF GYNECOLOGIC ONCOLOGY   30 巻 ( 6 ) 頁: e85   2019年11月

     詳細を見る

    記述言語:英語   出版者・発行元:Journal of Gynecologic Oncology  

    Objectives: There is increasing evidence that systemic inflammatory response (SIR) markers are prognostic factors for various types of cancers. This is the first study to evaluate the usefulness of SIR markers for the prognosis of early-stage ovarian clear-cell carcinoma (OCCC). Methods: We retrospectively investigated 83 patients diagnosed with stage I–II OCCC who underwent surgery between 2005 and 2017. Initially, receiver operating characteristic curve analysis for overall survival (OS) was used to determine optimal cut-off values for neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR). Patients were stratified into 2 groups by the cut-off values (NLR=3.26, PLR=160). Univariate and multivariate analyses were performed to elucidate the significance of SIR markers as prognostic factors. Results: In the median follow-up period of 64.1 months, 16 patients experienced recurrence, and nine patients died. The Kaplan-Meier curve showed that OS of the NLR-low group was significantly longer than the NLR-high group (p=0.021). There was no significant difference in progression-free survival between the 2 groups (p=0.668), but the post-recurrence survival of the NLR-low group was significantly longer than the NLR-high group (p=0.019). Furthermore, multivariate analysis showed that increase in NLR is a significant independent prognostic factor for poor prognosis (hazard ratio=7.437, p=0.017). There was no significant difference between PLR-low and PLR-high group. Conclusion: Results suggest that NLR can be a significant independent prognostic factor for early-stage OCCC.

    DOI: 10.3802/jgo.2019.30.e85

    Web of Science

    Scopus

    PubMed

  30. COMPREHENSIVE MIRNA SEQUENCING OF SQUAMOUS CELL CARCINOMA ARISING FROM OVARIAN MATURE TERATOMA

    Yoshida K., Yokoi A., Tamauchi S., Ikeda Y., Yoshikawa N., Nishino K., Niimi K., Suzuki S., Kajiyama H., Kikkawa F.

    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER   29 巻   頁: A544 - A545   2019年11月

  31. Does postoperative prophylactic irradiation of para-aortic lymph nodes reduce the risk of recurrence in uterine cervical cancer with positive pelvic lymph nodes?

    Yoshida Kosuke, Kajiyama Hiroaki, Yoshihara Masato, Ikeda Yoshiki, Yoshikawa Nobuhisa, Nishino Kimihiro, Utsumi Fumi, Niimi Kaoru, Suzuki Shiro, Kikkawa Fumitaka

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   24 巻 ( 5 ) 頁: 567 - 574   2019年5月

     詳細を見る

    記述言語:英語   出版者・発行元:International Journal of Clinical Oncology  

    Background: In cervical cancer, para-aortic lymph nodes are common sites of metastasis. The purpose of the study was to evaluate the clinical benefits of prophylactic irradiation as postoperative therapy. Methods: A retrospective cohort study was conducted during 2001–2015 at a single institution. Patients with a high risk of para-aortic lymph nodes recurrence were eligible for this study, and we identified patients who had pelvic lymph node metastasis and underwent radical surgery and concurrent chemo-radiotherapy. As a result, 33 and 46 patients were included in the treatment (prophylactic irradiation) and non-treatment groups, respectively. Baseline differences between the two groups were adjusted with the inverse probability of treatment weighting using propensity scores composed of the independent variables including age, stage, tumor size, pathological findings, lymph node status, and pathological subtypes. Results: In the 68-month median follow-up period (range 6–178 months), 25 patients experienced recurrence, and 17 patients were dead. After adjustment with the inverse probability of treatment weighting, the recurrence rates tended to decrease in the treatment group, but there was no significant difference between the two groups [treatment vs. non-treatment, 29.4% and 44.3%, respectively; hazard ratio, 0.593 (95% CI 0.320–1.099); P = 0.097]. However, adjusted para-aortic lymph nodes recurrence rates were not significantly different [treatment vs. non-treatment, 7.8% and 11.4%, respectively; odds ratio, 0.660 (95% CI 0.187–2.322); P = 0.558]. Moreover, Kaplan–Meier curves showing post-recurrence survival revealed no significant difference between the two groups (P = 0.141). Conclusions: Prophylactic para-aortic lymph nodes irradiation did not reduce the risk of recurrence.

    DOI: 10.1007/s10147-018-1376-2

    Web of Science

    Scopus

    PubMed

  32. PROPENSITY SCORE ADJUSTED ANALYSIS OF PROPHYLACTIC IRRADIATION TO PARA-AORTIC LYMPH NODE AFTER RADICAL HYSTERECTOMY FOR UTERINE CERVICAL CANCER.

    Yoshida K., Yoshihara M., Ikeda Y., Yoshikawa N., Nishino K., Utumi F., Niimi K., Suzuki S., Kajiyama H., Kikkawa F.

    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER   28 巻   頁: 447 - 447   2018年9月

     詳細を見る

  33. EFFECT OF CONCURRENT CHEMO-RADIOTHERAPY ON CLINICAL OUTCOMES IN SMALL CELL CARCINOMA OF THE UTERINE CERVIX

    Ikeda Y., Kajiyama H., Yoshida K., Yoshikawa N., Nishino K., Utsumi F., Niimi K., Suzuki S., Kawai M., Kikkawa F.

    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER   28 巻   頁: 294 - 294   2018年9月

     詳細を見る

  34. The upregulated expression of vascular endothelial growth factor in surgically treated patients with recurrent/radioresistant cervical cancer of the uterus

    Yoshida Kosuke, Suzuki Shiro, Sakata Jun, Utsumi Fumi, Niimi Kaoru, Yoshikawa Nobuhisa, Nishino Kimihiro, Shibata Kiyosumi, Kikkawa Fumitaka, Kajiyama Hiroaki

    ONCOLOGY LETTERS   16 巻 ( 1 ) 頁: 515 - 521   2018年7月

     詳細を見る

    記述言語:英語   出版者・発行元:Oncology Letters  

    Vascular endothelial growth factor (VEGF) inhibitors have been utilized for the treatment against advanced or recurrent cervical carcinoma as a novel therapeutic modality. However, the expression level of VEGF in post-radiotherapy relapsed/persistent cervical cancer remains to be elucidated. The aim of the present study was to investigate the expression of VEGF and associated molecules using tumor samples from patients with post-radiotherapy relapsed/persistent cervical cancer. From a database of 826 patients who were treated at our institution between 2003 and 2015, eight patients with post-radiotherapy relapsed/persistent cervical cancer were identified, and 20 patients who underwent initial surgery alone were used as a control. Using samples from these patients, the expression levels of VEGF-A, VEGF receptor-1 (VEGFR-1) and hypoxia inducible factor-1α (HIF-1α) were immunohisto-chemically categorized as negative or weakly, moderately, or strongly positive according to the size of the staining area, and intensity. In carcinoma cells, the expression levels of VEGF-A, VEGFR-1 and HIF-1α were significantly higher in post-radiotherapy relapsed/persistent cervical cancer compared with control patients (P=0.0003, 0.0003, and 0.0001, respectively). In stroma cells, similar tendencies with statistical significance were observed (P=0.0014 and P<0.0001, respectively). In addition, the expression levels of VEGF-A and VEGFR-1 in carcinoma cells were significantly correlated with each other (P<0.0001). A significantly higher expression of VEGF was identified in post-radiotherapy relapsed/persistent cervical cancer compared with typical specimens from cervical cancer. The findings provide a novel insight into the clinical treatment for recurrent/persistent cervical cancer using a VEGF antagonist.

    DOI: 10.3892/ol.2018.8610

    Web of Science

    Scopus

    PubMed

  35. A post-recurrence survival-predicting indicator for cervical cancer from the analysis of 165 patients who developed recurrence

    Yoshida Kosuke, Kajiyama Hiroaki, Utsumi Fumi, Niimi Kaoru, Sakata Jun, Suzuki Shiro, Shibata Kiyosumi, Kikkawa Fumitaka

    MOLECULAR AND CLINICAL ONCOLOGY   8 巻 ( 2 ) 頁: 281 - 285   2018年2月

  36. EVALUATING THE LONG TERM PROGNOSTIC FACTOR AND THE ROLE OF CYTOREDUCTION IN THE OVERALL POPULATION OF PATIENTS WITH CLINICAL AND SURGICAL STAGE IV ENDOMETRIAL CARCINOMA

    Shimizu Y., Kajiyama H., Suzuki S., Yoshikawa N., Nakamura K., Yoshihara M., Tamauchi S., Yoshida K., Kikkawa F.

    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER   27 巻   頁: 1213 - 1213   2017年11月

     詳細を見る

▼全件表示

科研費 2

  1. 難治性卵巣がんにおける細胞外小胞機能解析と臨床応用基盤創生

    研究課題/研究課題番号:21H03075  2021年4月 - 2024年3月

    科学研究費助成事業  基盤研究(B)

    横井 暁, 梶山 広明, 山本 雄介, 吉田 康将

      詳細を見る

    担当区分:研究分担者 

    本研究は、卵巣がんにおけるエクソソームを始めとした細胞外小胞(Extracellular Vesicle: EV)を対象とし、EVが有する未だ明らかにされていない腫瘍生物学的意義を明らかにし、臨床応用へ向けた基盤となる知見を得ることを目的とします。未だ臨床的問題点が多く残る難治性卵巣がんにおけるEVの機能解明は極めて重要と考えられます。本研究では、①卵巣がん悪性化に関わるEVの機能解析 ②個別化医療を実現するEVバイオマーカーの創出 ③EVによる難治進行性卵巣がんの新規治療開発の、3点を軸に研究を展開し、卵巣がん患者予後の改善に繋が成果を得ることを目指します。
    本研究は、卵巣がんにおけるエクソソームを始めとした細胞外小胞(Extracellular Vesicle: EV)を対象とし、EVが有する未だ明らかにされていない腫瘍生物学的意義を明らかにし、臨床応用へ向けた基盤となる知見を得ることを目的とする。あらゆる生細胞が恒常的に放出するEVは、細胞間情報伝達手段として注目されている。今後臨床応用へ向けたトランスレーショナル研究がさらに加速することが予想される一方で、EV研究はその定義や取扱いが未だ議論の的になるほど発展途上である。未だ臨床的問題点が多く残る難治性卵巣がんに於けるEVの機能解明は極めて重要と考えられる。本研究では、①卵巣がん悪性化に関わるEVの機能解析 ②個別化医療を実現するEVバイオマーカーの創出 ③EVによる難治進行性卵巣がんの新規治療開発 の、3点を軸に研究を展開し、卵巣がん患者予後の改善に繋がる成果を得ることを目的として展開する。①に関して、卵巣明細胞腺癌における薬剤耐性機構において、ChrXq27.3マイクロRNAクラスターが白金製剤耐性化に寄与することを発表した(Yoshida K, Yokoi A, Kajiyama H et al. Oncogene 2021)。また、VEGF含有エクソソームが卵巣がん患者におけるベバシズマブ体制に関与することを発表した(Ma S, Yokoi A, Sood AK et al., Cell reports 2021)。②に関して、免疫ワクチン療法の効果予測として血中のマイクロRNAプロファイルが有用であることを示した(Ukai M, Yokoi A, Kajiyama H et al. Cancers 2021)。③に関して、脂肪組織中に存在する間葉系幹細胞が放出するエクソソームが、がん細胞の増殖を抑制することを示し、日本癌学会学術集会にて報告した。
    3つの研究項目を提案したが、それぞれ順調に進行している。
    本研究期間3年の間に6つのマイルストーンを設定している。それぞれ進捗の程度は違うにせよおおむね問題なく進行しており、引き続き期間内の目的達成を目指す。

  2. 卵巣がん1細胞レベルでのマルチトランスクリプトーム解析による発がん機構の解明

    研究課題/研究課題番号:21K16789  2021年4月 - 2023年3月

    科学研究費助成事業  若手研究

    吉田 康将

      詳細を見る

    担当区分:研究代表者 

    配分額:4680000円 ( 直接経費:3600000円 、 間接経費:1080000円 )

    がん微小環境における多様性は、がんの進展に大きく関与している。近年、空間的トランスクリプトームおよびシングルセルトランスクリプトーム解析により、微小環境を高解像度で捉えることが可能になった。本研究では、子宮内膜症より生じる卵巣明細胞がんや類内膜がんを対象とし、がん組織とそれに連続する非がん部内膜症性嚢胞組織に対してこれらの解析を行う。これにより、双方の組織を構成する上皮系細胞および間質細胞の細胞集団レベルでの遺伝子発現変動を明らかにする。そして、上皮系細胞と間質細胞の相互作用を考察し、更なる機能解析を行うことで、発がん課程のごく初期において間質細胞が果たす役割を明らかにする。
    本研究の目的は、卵巣がんに対する一細胞解析・空間的トランスクリプト―ム等の解析を通して、その発がん・悪性化・薬剤抵抗性などに関与する遺伝子発現について解析を行うことである。現在までに、5例の卵巣成熟奇形腫の悪性転化に対して、一細胞解析および空間的トランスクリプトーム解析を行い、その微小環境の多様性について現在解析を行っている。卵巣成熟奇形腫の悪性転化は希少がんであり、その病態はほとんど明らかにされていない。臨床的には、良性腫瘍である成熟奇形腫から二次性に発がんすると考えられているが、具体的にどのような種類細胞が、どのようにして発がんするかは未解明である。今後、発がん・悪性化に関わると考えられる因子を同定し、細胞株やマウスモデル利用した研究によりその機能解析することにより、成熟奇形腫の悪性転化において重要な遺伝子等を明らかにする予定である。
    また、他の卵巣がんの組織型である漿液性がんに対しては、4例の空間的トランスクリプトーム解析を施行した。今後、薬剤感受性に関わる因子を同定し、その耐性化機序について研究を進める予定である。
    さらに、子宮平滑筋肉腫に対する新規治療薬を探索する研究も行い、論文発表を行った(Yoshida K. Clinical Cancer Research 2022)。子宮平滑筋肉腫は、極めて悪性度の高い婦人科悪性腫瘍であり、有効な治療方法は存在しない。今回、臨床検体のRNAシーケンスを通して、新規治療標的を同定し、その治療標的に対する阻害剤の前臨床的な効果を検証した。その結果、PLK1阻害剤およびCHEK1阻害剤が極めて高い抗腫瘍効果を示し、新規治療薬候補になり得ると結論づけた。
    既に次世代シーケンス解析によるデータは得られており、順調に研究が進んでいる。
    次世代シーケンスで得られたデータを詳細に解析することにより、有望な遺伝子を同定し、機能解析を行っていく予定である。